Monitor for IND filings (expected Q1 2027 for Armed-T and Q3 2027 for GDT) and any clinical trial updates as primary catalysts. The company's limited cash runway and lack of FDA progress warrant caution until meaningful clinical data emerges. The legacy exosome business decline and increasing R&D spend may pressure liquidity.
Price Chart
Executive Summary
SL Science Holding Limited (SLBT) filed its Form 20-F disclosing the completion of its business combination with SPAC Horizon Space Acquisition II Corp. on June 12, 2026, with an implied equity valuation of $5.568 billion and a concurrent $7.8 million PIPE financing. The filing reveals that SL Bio, the operating subsidiary, remains a pre-revenue cell therapy company with declining legacy revenue (down 35% to $2.2M), a net loss of $3.8M in 2025, and approximately $9M in pro forma cash, providing limited runway. No FDA approvals or IND filings have been achieved yet, with IND filings anticipated in 2027.
Key Facts
- Business combination closed June 12, 2026; SLBT shares began trading on Nasdaq on June 15, 2026.
- PIPE financing raised $7.8 million through 780,000 units at $10 each (one ordinary share + one convertible preferred share).
- SL Bio's net revenue declined 35% to $2,197,249 for the year ended December 31, 2025, from $3,363,603 in 2024.
- Net loss increased to $3,819,818 in 2025 from $1,191,333 in 2024.
- Cash and cash equivalents were $1,258,616 as of December 31, 2025; pro forma combined cash after PIPE is approximately $9.0 million.
- All product candidates (CD-19 Armed-T, GDT cell therapies for pancreatic and brain cancer) are in pre-clinical development; no IND has been filed with the FDA.
- No FDA approvals or clinical trial results have been achieved to date.
Financial Impact
Pro forma cash of ~$9M provides less than 2.5 years of runway at the current annual operating loss rate of ~$4M. No near-term revenue from cell therapy pipeline.
Risk Factors
- Pre-revenue cell therapy pipeline with no FDA approvals or clinical data.
- Declining revenue from legacy exosome/plant extract businesses.
- Limited cash runway (~2 years at current burn rate) with significant outstanding milestone payments to licensors.
- No IND filing yet; FDA feedback received in January 2026 indicated insufficient nonclinical and manufacturing data.
- Related party transactions and concentrated ownership (CEO controls ~59.5% of shares).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001213900-26-070158 |
| Document: ea029318401ex1-1.htm | 0001213900-26-070158 |
| Document: ea029318401ex15-1.htm | 0001213900-26-070158 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.24 | awaiting T+20 | — | $1.23 (−0.81%) |
Oct 26, 2026 today | Press Release | $1.24 | awaiting T+20 | — | $1.23 (−0.81%) |
Oct 1, 2026 25d ago | SC 13D/A | $1.57 | awaiting T+20 | — | $1.23 (−21.66%) |
Aug 13, 2026 10w ago | EFFECT | $2.71 $2.06 | ▼ −23.99% | ▼ −22.24% | $1.23 (−54.61%) |
Jul 31, 2026 12w ago | F-1 | $3.29 $2.73 | ▼ −17.02% | ▼ −18.26% | $1.23 (−62.61%) |
Jul 10, 2026 15w ago | 6-K | $4.73 $2.67 | ▼ −43.55% | ▼ −45.98% | $1.23 (−74.00%) |
Jun 18, 2026 18w ago | 20-F | $4.52 $4.30 | ▼ −4.87% | ▼ −4.72% | $1.23 (−72.79%) |
Jun 17, 2026 18w ago | 3 | $6.38 $4.33 | ▼ −32.13% | ▼ −33.45% | $1.23 (−80.72%) |
Jun 15, 2026 19w ago | 3 | $3.33 $4.33 | ▲ +30.03% | ▲ +30.78% | $1.23 (−63.06%) |
Jun 15, 2026 19w ago | 6-K | $3.33 $4.33 | ▲ +30.03% | ▲ +30.78% | $1.23 (−63.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers